Colorectal cancer Posts - Page 30 of 68 on Medivizor
Navigation Menu

Colorectal cancer Posts on Medivizor

Is treatment with CAPOX or capecitabine alone associated with improved survival rates in elderly colon cancer patients?

Is treatment with CAPOX or capecitabine alone associated with improved survival rates in elderly colon cancer patients?

Posted by on Oct 3, 2016 in Colorectal cancer | 1 comment

In a nutshell This study investigated the effects of CAPOX chemotherapy (oxaliplatin plus capecitabine) or capecitabine (Xeloda) alone on survival of elderly stage 3 colon cancer patients. Researchers suggested that both CAPOX or capecitabine alone were associated with an improved survival.  Some background Chemotherapy is the standard...

Read More

Uracil-tegafur and leucovorin is an effective and safe option for the treatment of liver metastasis in colorectal cancer

Uracil-tegafur and leucovorin is an effective and safe option for the treatment of liver metastasis in colorectal cancer

Posted by on Oct 3, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of uracil-tegafur and leucovorin (UFT/LV) treatment of liver metastasis (when the cancer spread to the liver) in colorectal cancer patients. Researchers suggested that UFT/LV is an effective and safe option for the treatment of liver metastasis after liver surgery.  Some background The...

Read More

Is laparoscopic surgery associated with better long-term outcomes in colorectal cancer?

Is laparoscopic surgery associated with better long-term outcomes in colorectal cancer?

Posted by on Sep 26, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the impact of laparoscopy (LPS) compared with open surgery on long-term outcomes of colorectal cancer patients. Researchers suggested that LPS is not associated with better long-term outcomes. Some background Colorectal LPS (removal of the tumor by using a cable with a camera inserted near the tumor) is a...

Read More

Neutrophil-to-lymphocyte ratio is a good predictor of post-surgery complications in colorectal cancer

Neutrophil-to-lymphocyte ratio is a good predictor of post-surgery complications in colorectal cancer

Posted by on Sep 26, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the association between the neutrophil-to-lymphocyte ratio (NLR) and complications after surgery in patients with colorectal cancer. Researchers suggested that NLR levels are associated with post-surgery complication rates. Some background A high number of patients with colorectal cancer suffer from...

Read More

Biofeedback therapy helps to treat side effects of surgery to rectal cancer

Biofeedback therapy helps to treat side effects of surgery to rectal cancer

Posted by on Sep 19, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of biofeedback therapy in rectal cancer patients with anterior resection syndrome (ARS) after rectal surgery. Researchers reported that this therapy can improve the anal function after rectal surgery. Some background ARS is a common condition after rectal surgery. Patients with this condition...

Read More

Lateral pelvic lymph node metastasis has a prognostic role in rectal cancer

Posted by on Sep 12, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the prognostic role of extramural tumor deposits (clusters of cancer cells not attached to the main tumor) in the pelvic area in rectal cancer. Researchers suggested that tumor deposits near the pelvic lymph nodes was a useful predictor of prognosis. Some background Colorectal cancer is one of the most common...

Read More

Tivozanib is as effective as bevacizumab when combined with mFOLFOX6 in metastatic colorectal cancer

Tivozanib is as effective as bevacizumab when combined with mFOLFOX6 in metastatic colorectal cancer

Posted by on Sep 12, 2016 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of the chemotherapy mFOLFOX6 combined with tivozanib (Tivopath) or bevacizumab (Avastin) in metastatic colorectal cancer. Researchers suggested that these two treatments are equally effective. Some background Roughly 20% of colorectal cancer patients have metastasis (spread to other parts of...

Read More

Is not undergoing surgery a safe treatment option in rectal cancer treatment?

Is not undergoing surgery a safe treatment option in rectal cancer treatment?

Posted by on Sep 5, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the outcomes of rectal cancer patients with complete or near-complete response to chemotherapy and radiation therapy (CRT) who do not undergo surgery. Researchers reported that not undergoing surgery, in selected patients, is a safe option for treatment of rectal cancer.  Some background The standard...

Read More

Increasing Awareness: What is Cachexia?

Increasing Awareness:  What is Cachexia?

Posted by on Aug 11, 2016 in Blog, Breast cancer, Colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 4 comments

Eating Together For many, being able to commune around a table–talking, laughing and eating–is a sign of health and well-being.  That’s why, when someone is sick, and doesn’t eat, conflict can result. Caregivers may feel enormous anxiety, guilt and hopelessness as their loved one loses weight. Yet, caregivers need to know what is...

Read More

Not just for headaches: Aspirin use during pre-surgery chemoradiation in rectal cancer

Posted by on Aug 8, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated whether aspirin has an effect against rectal cancer during pre-surgery chemotherapy and radiation therapy (CRT). Researchers reported that the use of aspirin is associated with a better outcome and survival. Some background Pre-surgery CRT has been shown to improve the rate of local recurrences (when the...

Read More

FOLFIRI or mFOLFOX6 plus bevacizumab are equally efficient as treatment for metastatic colorectal cancer

FOLFIRI or mFOLFOX6 plus bevacizumab are equally efficient as treatment for metastatic colorectal cancer

Posted by on Aug 8, 2016 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of the chemotherapies FOLFIRI plus bevacizumab (Avastin) and mFOLFOX6 plus bevacizumab in metastatic colorectal cancer. Researchers suggested that these two treatments are equally effective. Some background Roughly 20% of colorectal cancer patients have metastasis (spread to other...

Read More